Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TSEAC to discuss BSE

This article was originally published in The Tan Sheet

Executive Summary

FDA Transmissible Spongiform Encephalopathies Advisory Committee will meet July 17-18 to consider whether results of five gelatin studies conducted with European Commission funding demonstrate a reduction in infectivity from BSE sufficient to protect human health. Committee will discuss safety of bovine bone gelatin in oral and topical drugs, cosmetics and recommend changes to FDA position if necessary. All five studies, released July 11 on 1FDA's Web site, tested "gelatin manufacturing processes...using artificially high infective raw material [and] resulted in a final gelatin which, after purification, has not induced TBSE disease after intracerebral injection in animals of the same species." TSEAC meeting will take place at the Holiday Inn, 8120 Wisconsin Ave., Bethesda, Md...

You may also be interested in...



FDA TSE Bovine Gelatin Guidance Revisions Recommended By Panel

FDA should clarify its recommendations to industry about safe sources of bovine bone gelatin for use in dietary supplements, drugs and cosmetics, a majority of the agency's Transmissible Spongiform Encephalopathies Advisory Committee agreed at a July 17 meeting in Bethesda, Md

Mylan Weighs In On Coronavirus Drug Shortage Concerns

Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business. 

 

Eyes On Pricing As Zolgensma Moves Closer To Japan Market

Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.

Topics

UsernamePublicRestriction

Register

PS095698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel